In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rapicort Drug Master File in Korea (Rapicort KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rapicort. The MFDS reviews the Rapicort KDMF as part of the drug registration process and uses the information provided in the Rapicort KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rapicort KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rapicort API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rapicort suppliers with KDMF on PharmaCompass.